Accueil » Panels

Panels

MERCREDI - 6 OCTOBRE 2010

• Salon Rose - 14h00 - 17h00
  SÉANCE SUR LE FINANCEMENT INTERNATIONAL

  Présidente de séance :   Ginette Audet, Montréal International

  Modérateur :   Stephen M. Nagler, TriState Ventures LLC

  BioContact Quebec accueillera deux comités de grans spécialistes du monde financier des États-Unis. Tous travaillent entièrement ou en grande partie dans le domaine des sciences de la vie et souhaitent intensifier leur collaboration avec des sociétés canadiennes.

  Le premier comitéd’experts sera constitué d’investisseurs de capital de risque. Le second sera composé de représentatns de grandes sociétés pharmaceutiques, ouverts à des alliances stratégiques avec de plus petites sociétés. Il sera question d’opérations sous licence, d’accords de co-développement, de marketing, etc.

  Les deux comités discuteront des critères d’investissement, des stades de développement, des modalités et des intérêts effectifs.

  Capital de risque

  Ann Hanham Todd Foley James Huang Jennifer F. Goldstein James Garvey

  Burrill & Co. MPM Capital Vivo Ventures Pfizer SVLS

  
  
  

  Industrie

  « How to Make a Deal With A Major Pharmaceutical Company »

  Savino DiPasquale William Kuziel David Brener Axel Risse

  GlaxoSmithKline Daichi Sankyo Pfizer Sanofi-Aventis

THURSDAY, OCTOBER 7TH 2010

• Foyer de la
  Salle de bal
  8h30 - 9h30
  Getting Funded: Canadian Success Stories
  CEOs of two Canadian life sciences companies that achieved successful VC fundings in the past several years, as well as the Canadian and US VCs that funded them.

  Co-Moderators:
  Stephen Hurwitz and Brenda Jarrell Ph.D.
  Partners
  Choate, Hall & Stewart LLP

  Panelists:
  Charles Bishop, Ph.D., President and CEO, Cytochroma
  Luc Marengere, Ph.D., Managing General Partner, VG Partners
  Robert Heft, Ph.D., President and CEO, Enobia
  David Bonita, M.D., Principal, OrbiMed

  "Getting Funded: Canadian Success Stories"  and will have the following focus:

  In the past several years, when there have been few financings for Canadian life sciences companies, some have succeeded.   What is their secret?   We will showcase two Canadian companies (Cytochroma and Enobia) that got funded during that period as well as their respective Canadian and US investors (VG Partners and OrbiMed).   The purpose of the panel is to illustrate some important successes, and above all, to celebrate them. Together these companies and their investors will tell the story of why it worked (when for others it didn't).  The panelists will reveal the creative strategies and tactics utilized by these winning companies in their approaches to investors and why and how these investors were won over. The investors will also share stories as to companies they have not funded and what went wrong.  Our singular goal is to impart special insights to our audience that will enhance their chances of getting funded, and especially, to inspire them to believe that, even in this difficult period, funding can be within reach.

• 10h30 - 12h00
  Running on Empty? Access Capital from Alternate Sources

  Some companies have found innovative ways to raise capital. A panel of leading experts and entrepreneurs will share their financing experience and discuss innovative funding and partnership opportunities. The panellists will address several topics, including accessing equity lines of credit, pharma MNE and biopharma SME strategic alliances, enhancement of foreign VC opportunities through the removal of section 116, the monetization of drug royalty streams, as well as other financing models.

  Chair  :   George A. Michaliszyn, Ph.D. Director, Life Science Industries Branch, Industry Canada

  Moderator  :   Wayne Schnarr, MBA, Ph.D. Health Care Consultant TMX/Equicom

  Panel Members  :   
  Stephen A. Hurwitz, Partner, Choate, Hall & Stewart LLP
  Donald J. McCaffrey, President and CEO, Resverlogix
  Edward Harrington, V.P. & CFO, Roche Canada
  Pierre Soulard, LL.B., Partner, Ogilvy Renault LLP
  Scott Cormack, President and CEO, OncoGenex (invited)
  Michael Fusco, Managing Director, Morgan Stanley (invited)

* Présentés en anglais